Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Conditions

• Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• bevacizumab — BIOLOGICAL
• pemetrexed disodium — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving pemetrexed disodium together with bevacizumab may be an effective treatment for non-small cell lung cancer. PURPOSE: This phase II trial is studying how well giving pemetrexed disodium together with bevacizumab works in treating patients with stage III or stage IV non-small cell lung cancer.

Key Dates

First listed

Dec 22, 2005

Start date

May 31, 2006

Status verified

Jul 2016

Primary completion

May 31, 2007

Completion

Apr 30, 2010

Study Design

Enrollment

48 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: pemetrexed + bevacizumab
  Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for 5 years.

Primary Outcome Measure

Proportion of progression-free patients at 3 months [ Time Frame: at 3 months ]

Locations (248)

Find similar trials in Anchorage, AK

Related Studies

• Detection of Genetic Markers of Lung Cancer
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Lung Cancer Biomarkers and Screening
  Recruiting · NYU Langone Health · New York, New York
• DNA Analysis of Blood and Tissue from Patients with Lung Cancer
  Recruiting · Massachusetts General Hospital · Boston, Massachusetts
• Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
  Recruiting · Stanford University · Stanford, California